{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:28:58Z","timestamp":1787020138906,"version":"build-2736575974"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:00:00Z","timestamp":1776211200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T00:00:00Z","timestamp":1776384000000},"content-version":"vor","delay-in-days":2,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100009367","name":"Mansoura University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100009367","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cardiovasc Disord"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Acute heart failure (AHF) often occurs concurrently with renal impairment, forming the clinical entity known as cardiorenal syndrome. Conventional biomarkers frequently do not identify early renal impairment in patients with AHF.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>The present study aimed to assess the clinical applicability of fibroblast growth factor-23 (FGF23), soluble urokinase plasminogen activator receptor (SuPAR), and N-acetyl-\u03b2-D-glucosaminidase (NAG) as potential biomarkers for the discrimination of kidney disease in the setting of AHF.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and methods<\/jats:title>\n                    <jats:p>\n                      This prospective observational pilot study\u2002was performed from 2024 to 2025 in the critical care units of Mansoura University. In total, 80 subjects were included and classified into four groups: healthy controls\u2002(\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200920), renal disease group (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200920), AHF patients (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200920), and patients with combined AHF and renal dysfunction (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200920). Patients\u2019 clinical, demographic, and\u2002laboratory data were recorded at the admission. Serum FGF23\u2002and SuPAR were detected by ELISA, and NAG expression was analyzed by real-time quantitative PCR with internal control normalization. Statistical methods consisted of\u2002ANOVAs, Kruskal\u2013Wallis analyses, chi-square tests, Spearman\u2019s correlations, and receiver operating characteristic (ROC) curves, plus logistic regression with\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05 indicative of statistical significance.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The AUC of FGF-23 and SuPAR to differentiate AHF from renal disease was 0.792, with an accuracy of 82.5%, greater than those of the parameters. FGF23\u2002and SuPAR well distinguished RIF-AHF (AUC\u2009&gt;\u20090.96). The NAG gene performed at\u2002100% sensitivity and specificity with an AUC of 1.0 to distinguish AHF, RD, and MCR from controls. The association of NAG concentration with inflammatory markers, acid\u2013base disturbances, hypoxia indices, and renal function parameters indicated early tubular injury. NAG detected coincident clinical strata\u2002with excellent sensitivity even though its specificity was much lower.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>FGF23, SuPAR, and NAG are strong discriminators of early-stage\u2002cardiorenal dysfunction in AHF. NAG\u2002gene expression, in particular, exhibits excellent diagnostic performance and mirrors important pathophysiological processes before conventional biomarkers. Admission, follow-up, and the response of these biomarkers to treatment could improve early diagnosis, risk\u2002stratification, and clinical management in patients with AHF and renal dysfunction.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12872-026-05777-x","type":"journal-article","created":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T07:05:25Z","timestamp":1776236725000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["From heart to kidney: FGF23, SuPAR, and NAG as early biomarkers of cardiorenal syndrome in acute heart failure"],"prefix":"10.1186","volume":"26","author":[{"given":"Islam M.","family":"El-Desouki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nevin A.","family":"Salah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanaa M. M. Abdel","family":"Aziz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omali Y.","family":"El\u2011khawaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,15]]},"reference":[{"key":"5777_CR1","doi-asserted-by":"publisher","first-page":"15","DOI":"10.21037\/amj.2020.03.03","volume":"5","author":"G Lippi","year":"2020","unstructured":"Lippi G, Sanchis-Gomar F. Global Epidemiology and Future Trends of Heart Failure. AME Med J. 2020;5:15\u201315. https:\/\/doi.org\/10.21037\/amj.2020.03.03.","journal-title":"AME Med J"},{"key":"5777_CR2","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.42081","author":"A Ullah","year":"2023","unstructured":"Ullah A, Sajid S, Qureshi M, Kamran M, Anwaar M. A., Naseem M. A., Zaman M. U., Mahmood F., Rehman A., Shehryar A., Nadeem M. A. Novel Biomarkers and the Multiple-Marker Approach in Early Detection, Prognosis, and Risk Stratification of Cardiac Diseases: A Narrative Review. Cureus. 2023. https:\/\/doi.org\/10.7759\/cureus.42081.","journal-title":"Cureus"},{"issue":"4","key":"5777_CR3","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1002\/ejhf.1697","volume":"22","author":"W Mullens","year":"2020","unstructured":"Mullens W, Damman K, Testani JM, Martens P, Mueller C, Lassus J, Tang WHW, Skouri H, Verbrugge FH, Orso F, Hill L, Ural D, Lainscak M, Rossignol P, Metra M, Mebazaa A, Seferovic P, Ruschitzka F, Coats A. Evaluation of Kidney Function throughout the Heart Failure Trajectory \u2013 a Position Statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2020;22(4):584\u2013603. https:\/\/doi.org\/10.1002\/ejhf.1697.","journal-title":"Eur J Heart Fail"},{"issue":"feb05 19","key":"5777_CR4","doi-asserted-by":"publisher","first-page":"h411","DOI":"10.1136\/bmj.h411","volume":"350","author":"K Dharmarajan","year":"2015","unstructured":"Dharmarajan K, Hsieh AF, Kulkarni VT, Lin Z, Ross JS, Horwitz LI, Kim N, Suter LG, Lin H, Normand S-LT, Krumholz HM. Trajectories of Risk after Hospitalization for Heart Failure, Acute Myocardial Infarction, or Pneumonia: Retrospective Cohort Study. BMJ. 2015;350(feb05 19):h411\u2013411. https:\/\/doi.org\/10.1136\/bmj.h411.","journal-title":"BMJ"},{"issue":"2","key":"5777_CR5","doi-asserted-by":"publisher","first-page":"81","DOI":"10.36628\/ijhf.2020.0036","volume":"3","author":"N Wettersten","year":"2021","unstructured":"Wettersten N. Biomarkers in Acute Heart Failure: Diagnosis, Prognosis, and Treatment. Int J Heart Fail. 2021;3(2):81. https:\/\/doi.org\/10.36628\/ijhf.2020.0036.","journal-title":"Int J Heart Fail"},{"issue":"1","key":"5777_CR6","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.jacc.2003.07.031","volume":"43","author":"DE Forman","year":"2004","unstructured":"Forman DE, Butler J, Wang Y, Abraham WT, O\u2019Connor CM, Gottlieb SS, Loh E, Massie BM, Rich MW, Stevenson LW, Young JB, Krumholz HM. Incidence, Predictors at Admission, and Impact of Worsening Renal Function among Patients Hospitalized with Heart Failure. JACC. 2004;43(1):61\u20137. https:\/\/doi.org\/10.1016\/j.jacc.2003.07.031.","journal-title":"JACC"},{"issue":"5","key":"5777_CR7","doi-asserted-by":"publisher","first-page":"2658","DOI":"10.3390\/ijms25052658","volume":"25","author":"C Xu","year":"2024","unstructured":"Xu C, Tsihlis G, Chau K, Trinh K, Rogers NM, Julovi SM. Novel Perspectives in Chronic Kidney Disease-Specific Cardiovascular Disease. Int J Mol Sci. 2024;25(5):2658. https:\/\/doi.org\/10.3390\/ijms25052658.","journal-title":"Int J Mol Sci"},{"issue":"12","key":"5777_CR8","doi-asserted-by":"publisher","first-page":"4263","DOI":"10.1093\/ndt\/gfs375","volume":"27","author":"D Fliser","year":"2012","unstructured":"Fliser D, Laville M, Covic A, Fouque D, Vanholder R, Juillard L, Van Biesen WA. European Renal Best Practice (ERBP) Position Statement on the Kidney Disease Improving Global Outcomes (KDIGO) Clinical Practice Guidelines on Acute Kidney Injury: Part 1: Definitions, Conservative Management and Contrast-Induced Nephropathy. Nephrol Dialysis Transplantation. 2012;27(12):4263\u201372. https:\/\/doi.org\/10.1093\/ndt\/gfs375.","journal-title":"Nephrol Dialysis Transplantation"},{"key":"5777_CR9","doi-asserted-by":"publisher","first-page":"632260","DOI":"10.3389\/fphys.2021.632260","volume":"12","author":"S V\u00e1zquez-S\u00e1nchez","year":"2021","unstructured":"V\u00e1zquez-S\u00e1nchez S, Poveda J, Navarro-Garc\u00eda JA, Gonz\u00e1lez-Lafuente L, Rodr\u00edguez-S\u00e1nchez E, Ruilope LM, Ruiz-Hurtado G. An Overview of FGF-23 as a Novel Candidate Biomarker of Cardiovascular Risk. Front Physiol. 2021;12:632260. https:\/\/doi.org\/10.3389\/fphys.2021.632260.","journal-title":"Front Physiol"},{"issue":"19","key":"5777_CR10","doi-asserted-by":"publisher","first-page":"9740","DOI":"10.3390\/ijms26199740","volume":"26","author":"B-\u0218 Profire","year":"2025","unstructured":"Profire B-\u0218, Lupa\u0219cu FG, St\u0103tescu C, \u0218orodoc V, Sasc\u0103u R-A, Profire L, \u0218orodoc L. Heart Failure Biomarkers\u2014Pathophysiology, Diagnosis, Prognosis and Clinical Relevance. Int J Mol Sci. 2025;26(19):9740. https:\/\/doi.org\/10.3390\/ijms26199740.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"5777_CR11","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.cardfail.2022.08.010","volume":"29","author":"SS Hayek","year":"2023","unstructured":"Hayek SS, Tahhan AS, Ko Y-A, Alkhoder A, Zheng S, Bhimani R, Hartsfield J, Kim J, Wilson P, Shaw L, Wei C, Reiser J, Quyyumi AA. Soluble Urokinase Plasminogen Activator Receptor Levels and Outcomes in Patients with Heart Failure. J Card Fail. 2023;29(2):158\u201367. https:\/\/doi.org\/10.1016\/j.cardfail.2022.08.010.","journal-title":"J Card Fail"},{"issue":"5","key":"5777_CR12","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1172\/JCI124793","volume":"129","author":"C Wei","year":"2019","unstructured":"Wei C, Li J, Adair BD, Zhu K, Cai J, Merchant M, Samelko B, Liao Z, Koh KH, Tardi NJ, Dande RR, Liu S, Ma J, Dibartolo S, H\u00e4gele S, Peev V, Hayek SS, Cimbaluk DJ, Tracy M, Klein J, Sever S, Shattil SJ, Arnaout MA, Reiser J. UPAR Isoform 2 Forms a Dimer and Induces Severe Kidney Disease in Mice. J Clin Invest. 2019;129(5):1946\u201359. https:\/\/doi.org\/10.1172\/JCI124793.","journal-title":"J Clin Invest"},{"issue":"3","key":"5777_CR13","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1681\/ASN.2006030221","volume":"18","author":"O Liangos","year":"2007","unstructured":"Liangos O, Perianayagam MC, Vaidya VS, Han WK, Wald R, Tighiouart H, MacKinnon RW, Li L, Balakrishnan VS, Pereira BJG, Bonventre JV, Jaber BL. Urinary N-Acetyl-\u03b2-(D)-Glucosaminidase Activity and Kidney Injury Molecule-1 Level Are Associated with Adverse Outcomes in Acute Renal Failure. J Am Soc Nephrol. 2007;18(3):904\u201312. https:\/\/doi.org\/10.1681\/ASN.2006030221.","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"5777_CR14","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/s11897-022-00557-y","volume":"19","author":"B Roehm","year":"2022","unstructured":"Roehm B, McAdams M, Hedayati SS. Novel Biomarkers of Kidney Disease in Advanced Heart Failure: Beyond GFR and Proteinuria. Curr Heart Fail Rep. 2022;19(4):223\u201335. https:\/\/doi.org\/10.1007\/s11897-022-00557-y.","journal-title":"Curr Heart Fail Rep"},{"key":"5777_CR15","unstructured":"Origene.com. NAGA Human qPCR Primer Pair (NM_000262). https:\/\/www.origene.com\/catalog\/gene-expression\/qpcr-primer-pairs\/hp200244-naga-human-qpcr-primer-pair-nm-000262."},{"issue":"2","key":"5777_CR16","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/s10741-018-9673-4","volume":"23","author":"P Di Nicol\u00f2","year":"2018","unstructured":"Di Nicol\u00f2 P. The Dark Side of the Kidney in Cardio-Renal Syndrome: Renal Venous Hypertension and Congestive Kidney Failure. Heart Fail Rev. 2018;23(2):291\u2013302. https:\/\/doi.org\/10.1007\/s10741-018-9673-4.","journal-title":"Heart Fail Rev"},{"issue":"02","key":"5777_CR17","doi-asserted-by":"publisher","first-page":"83","DOI":"10.4149\/BLL_2015_015","volume":"116","author":"E Demesova","year":"2015","unstructured":"Demesova E, Goncalvesova E, Slezak P, Pontuch P. Functional and Circulatory Renal Changes in Advanced Heart Failure. Bratislava Med J. 2015;116(02):83\u20137. https:\/\/doi.org\/10.4149\/BLL_2015_015.","journal-title":"Bratislava Med J"},{"key":"5777_CR18","doi-asserted-by":"publisher","unstructured":"Rangaswami J, Bhalla V, Blair JEA, Chang TI, Costa S, Lentine KL, Lerma EV, Mezue K, Molitch M, Mullens W, Ronco C, Tang WHW, McCullough PA. Cardiorenal Syndrome: Classification, Pathophysiology, Diagnosis, and Treatment Strategies: A Scientific Statement From the American Heart Association. Circulation. 2019;139(16). https:\/\/doi.org\/10.1161\/CIR.0000000000000664.","DOI":"10.1161\/CIR.0000000000000664"},{"issue":"2","key":"5777_CR19","doi-asserted-by":"publisher","first-page":"79","DOI":"10.33176\/AACB-18-00017","volume":"40","author":"TT van Duijl","year":"2019","unstructured":"van Duijl TT, Ruhaak LR, de Fijter JW, Cobbaert CM. Kidney Injury Biomarkers in an Academic Hospital Setting: Where Are We Now? Clin Biochemist Reviews. 2019;40(2):79\u201397. https:\/\/doi.org\/10.33176\/AACB-18-00017.","journal-title":"Clin Biochemist Reviews"},{"issue":"11","key":"5777_CR20","doi-asserted-by":"publisher","first-page":"4393","DOI":"10.1172\/JCI46122","volume":"121","author":"C Faul","year":"2011","unstructured":"Faul C, Amaral AP, Oskouei B, Hu M-C, Sloan A, Isakova T, Guti\u00e9rrez OM, Aguillon-Prada R, Lincoln J, Hare JM, Mundel P, Morales A, Scialla J, Fischer M, Soliman EZ, Chen J, Go AS, Rosas SE, Nessel L, Townsend RR, Feldman HI, St. John Sutton M, Ojo A, Gadegbeku C, Di Marco GS, Reuter S, Kentrup D, Tiemann K, Brand M, Hill JA, Moe OW, Kuro-o M, Kusek JW, Keane MG, Wolf M. FGF23 Induces Left Ventricular Hypertrophy. J Clin Invest. 2011;121(11):4393\u2013408. https:\/\/doi.org\/10.1172\/JCI46122.","journal-title":"J Clin Invest"},{"issue":"6","key":"5777_CR21","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1016\/j.cmet.2015.09.002","volume":"22","author":"A Grabner","year":"2015","unstructured":"Grabner A, Amaral AP, Schramm K, Singh S, Sloan A, Yanucil C, Li J, Shehadeh LA, Hare JM, David V, Martin A, Fornoni A, Di Marco GS, Kentrup D, Reuter S, Mayer AB, Pavenst\u00e4dt H, Stypmann J, Kuhn C, Hille S, Frey N, Leifheit-Nestler M, Richter B, Haffner D, Abraham R, Bange J, Sperl B, Ullrich A, Brand M, Wolf M, Faul C. Activation of Cardiac Fibroblast Growth Factor Receptor 4 Causes Left Ventricular Hypertrophy. Cell Metab. 2015;22(6):1020\u201332. https:\/\/doi.org\/10.1016\/j.cmet.2015.09.002.","journal-title":"Cell Metab"},{"issue":"19","key":"5777_CR22","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1161\/CIRCULATIONAHA.108.844506","volume":"119","author":"OM Guti\u00e9rrez","year":"2009","unstructured":"Guti\u00e9rrez OM, Januzzi JL, Isakova T, Laliberte K, Smith K, Collerone G, Sarwar A, Hoffmann U, Coglianese E, Christenson R, Wang TJ, deFilippi C, Wolf M. Fibroblast Growth Factor 23 and Left Ventricular Hypertrophy in Chronic Kidney Disease. Circulation. 2009;119(19):2545\u201352. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.108.844506.","journal-title":"Circulation"},{"issue":"2","key":"5777_CR23","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1681\/ASN.2013050465","volume":"25","author":"JJ Scialla","year":"2014","unstructured":"Scialla JJ, Xie H, Rahman M, Anderson AH, Isakova T, Ojo A, Zhang X, Nessel L, Hamano T, Grunwald JE, Raj DS, Yang W, He J, Lash JP, Go AS, Kusek JW, Feldman H, Wolf M. Fibroblast Growth Factor-23 and Cardiovascular Events in CKD. J Am Soc Nephrol. 2014;25(2):349\u201360. https:\/\/doi.org\/10.1681\/ASN.2013050465.","journal-title":"J Am Soc Nephrol"},{"issue":"18","key":"5777_CR24","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.3760\/cma.j.issn.0376-2491.2019.18.007","volume":"99","author":"YY Huo","year":"2019","unstructured":"Huo YY, Bai XJ, Han LL, Wang N, Han W, Sun XF. [Association of Fibroblast Growth Factor 23 with Age-Related Cardiac Diastolic Function Subclinical State in a Healthy Chinese Population]. Zhonghua Yi Xue Za Zhi. 2019;99(18):1390\u20136. https:\/\/doi.org\/10.3760\/cma.j.issn.0376-2491.2019.18.007.","journal-title":"Zhonghua Yi Xue Za Zhi"},{"issue":"3","key":"5777_CR25","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1161\/CIRCHEARTFAILURE.113.000952","volume":"7","author":"B Kestenbaum","year":"2014","unstructured":"Kestenbaum B, Sachs MC, Hoofnagle AN, Siscovick DS, Ix JH, Robinson-Cohen C, Lima JAC, Polak JF, Blondon M, Ruzinski J, Rock D, de Boer. I. H. Fibroblast Growth Factor-23 and Cardiovascular Disease in the General Population. Circ Heart Fail. 2014;7(3):409\u201317. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.113.000952.","journal-title":"Circ Heart Fail"},{"issue":"4","key":"5777_CR26","doi-asserted-by":"publisher","first-page":"39","DOI":"10.3390\/jvd4040039","volume":"4","author":"D Jain","year":"2025","unstructured":"Jain D, Prasad A, Shahi H, Wadhera N, Goel A, Sethi Y, The HEART-FGF, Study. Cardiovascular Remodeling and Risk Stratification by FGF-23 in Patients with CKD: An Integrative Cross-Sectional Study of Cardiac, Renal, and Mineral Parameters. J Vascular Dis. 2025;4(4):39. https:\/\/doi.org\/10.3390\/jvd4040039.","journal-title":"J Vascular Dis"},{"issue":"2","key":"5777_CR27","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1681\/ASN.2013050465","volume":"25","author":"JJ Scialla","year":"2014","unstructured":"Scialla JJ, Xie H, Rahman M, Anderson AH, Isakova T, Ojo A, Zhang X, Nessel L, Hamano T, Grunwald JE, Raj DS, Yang W, He J, Lash JP, Go AS, Kusek JW, Feldman H, Wolf M. Fibroblast Growth Factor-23 and Cardiovascular Events in CKD. J Am Soc Nephrol. 2014;25(2):349\u201360. https:\/\/doi.org\/10.1681\/ASN.2013050465.","journal-title":"J Am Soc Nephrol"},{"issue":"19","key":"5777_CR28","doi-asserted-by":"publisher","first-page":"9740","DOI":"10.3390\/ijms26199740","volume":"26","author":"B-\u0218 Profire","year":"2025","unstructured":"Profire B-\u0218, Lupa\u0219cu FG, St\u0103tescu C, \u0218orodoc V, Sasc\u0103u R-A, Profire L, \u0218orodoc L. Heart Failure Biomarkers\u2014Pathophysiology, Diagnosis, Prognosis and Clinical Relevance. Int J Mol Sci. 2025;26(19):9740. https:\/\/doi.org\/10.3390\/ijms26199740.","journal-title":"Int J Mol Sci"},{"key":"5777_CR29","doi-asserted-by":"publisher","unstructured":"Ivey-Miranda JB, Stewart B, Cox ZL, McCallum W, Maulion C, Gleason O, Meegan G, Amatruda JG, Moreno-Villagomez J, Mahoney D, Turner JM, Wilson FP, Estrella MM, Shlipak MG, Rao VS, Testani JM. FGF-23 (Fibroblast Growth Factor-23) and Cardiorenal Interactions. Circ Heart Fail. 2021;14(11). https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.121.008385.","DOI":"10.1161\/CIRCHEARTFAILURE.121.008385"},{"issue":"7","key":"5777_CR30","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1038\/s41581-020-0276-7","volume":"16","author":"S Faubel","year":"2020","unstructured":"Faubel S, SuPAR:. A Potential Predictive Biomarker for Acute Kidney Injury. Nat Rev Nephrol. 2020;16(7):375\u20136. https:\/\/doi.org\/10.1038\/s41581-020-0276-7.","journal-title":"Nat Rev Nephrol"},{"issue":"2","key":"5777_CR31","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.cardfail.2022.08.010","volume":"29","author":"SS Hayek","year":"2023","unstructured":"Hayek SS, Tahhan AS, Ko Y-A, Alkhoder A, Zheng S, Bhimani R, Hartsfield J, Kim J, Wilson P, Shaw L, Wei C, Reiser J, Quyyumi AA. Soluble Urokinase Plasminogen Activator Receptor Levels and Outcomes in Patients with Heart Failure. J Card Fail. 2023;29(2):158\u201367. https:\/\/doi.org\/10.1016\/j.cardfail.2022.08.010.","journal-title":"J Card Fail"},{"key":"5777_CR32","doi-asserted-by":"publisher","first-page":"132071","DOI":"10.1016\/j.ijcard.2024.132071","volume":"406","author":"J Chew-Harris","year":"2024","unstructured":"Chew-Harris J, Frampton C, Greer C, Appleby S, Pickering JW, Kuan W, Sen; Ibrahim I, Chan SP, Li Z, Liew OW, Adamson PD, Troughton R, Tan LL, Lin W, Ooi SBS, Richards AM, Pemberton CJ. Prognostic Performance of Soluble Urokinase Plasminogen Activator Receptor for Heart Failure or Mortality in Western and Asian Patients with Acute Breathlessness. Int J Cardiol. 2024;406:132071. https:\/\/doi.org\/10.1016\/j.ijcard.2024.132071.","journal-title":"Int J Cardiol"},{"issue":"1","key":"5777_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10157-022-02300-2","volume":"27","author":"Y Huang","year":"2023","unstructured":"Huang Y, Huang S, Zhuo X, Lin M. Predictive Value of SuPAR in AKI: A Systematic Review and Meta-Analysis. Clin Exp Nephrol. 2023;27(1):1\u201311. https:\/\/doi.org\/10.1007\/s10157-022-02300-2.","journal-title":"Clin Exp Nephrol"},{"key":"5777_CR34","doi-asserted-by":"publisher","unstructured":"Huet F, Dupuy A-M, Duflos C, Reis CA, Kuster N, Aguilhon S, Cristol J-P, Roubille F. Soluble Urokinase-Type Plasminogen Activator Receptor Strongly Predicts Global Mortality in Acute Heart Failure Patients: Insight From the STADE-HF Registry. Future Sci OA. 2021;7(5). https:\/\/doi.org\/10.2144\/fsoa-2020-0197.","DOI":"10.2144\/fsoa-2020-0197"},{"issue":"6","key":"5777_CR35","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1016\/S0272-6386(12)80603-2","volume":"18","author":"RE Schmieder","year":"1991","unstructured":"Schmieder RE, Rockstroh JK, M\u00fcnch HG, R\u00fcddel H, Schlebusch H. Elevated Serum Activity of N-Acetyl-\u03b2-Glucosaminidase in Essential Hypertension: Diagnostic Value and Reversal to Normal Values After Antihypertensive Therapy. Am J Kidney Dis. 1991;18(6):638\u201348. https:\/\/doi.org\/10.1016\/S0272-6386(12)80603-2.","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"5777_CR36","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1007\/s13205-019-1593-z","volume":"9","author":"K Siddiqui","year":"2019","unstructured":"Siddiqui K, Al-Malki B, George TP, Nawaz SS, Rubeaan K. Al. Urinary N-Acetyl-Beta-d-Glucosaminidase (NAG) with Neutrophil Gelatinase-Associated Lipocalin (NGAL) Improves the Diagnostic Value for Proximal Tubule Damage in Diabetic Kidney Disease. 3 Biotech. 2019;9(3):66. https:\/\/doi.org\/10.1007\/s13205-019-1593-z.","journal-title":"3 Biotech"},{"issue":"4","key":"5777_CR37","doi-asserted-by":"publisher","first-page":"444","DOI":"10.3390\/bioengineering10040444","volume":"10","author":"R Novak","year":"2023","unstructured":"Novak R, Salai G, Hrkac S, Vojtusek IK, Grgurevic L. Revisiting the Role of NAG across the Continuum of Kidney Disease. Bioengineering. 2023;10(4):444. https:\/\/doi.org\/10.3390\/bioengineering10040444.","journal-title":"Bioengineering"},{"issue":"4","key":"5777_CR38","doi-asserted-by":"publisher","first-page":"444","DOI":"10.3390\/bioengineering10040444","volume":"10","author":"R Novak","year":"2023","unstructured":"Novak R, Salai G, Hrkac S, Vojtusek IK, Grgurevic L. Revisiting the Role of NAG across the Continuum of Kidney Disease. Bioengineering. 2023;10(4):444. https:\/\/doi.org\/10.3390\/bioengineering10040444.","journal-title":"Bioengineering"},{"key":"5777_CR39","doi-asserted-by":"publisher","unstructured":"Zhao T, Chen G, Zhu S, Zhao C, Jin C, Xie Y, Xiang M. Prognostic Value of Urinary N-Acetyl-\u03b2-d-Glucosaminidase as a Marker of Tubular Damage in Patients with Heart Failure and Mitral Regurgitation. Rev Cardiovasc Med. 2023;24(8). https:\/\/doi.org\/10.31083\/j.rcm2408219.","DOI":"10.31083\/j.rcm2408219"},{"issue":"0","key":"5777_CR40","doi-asserted-by":"publisher","first-page":"0","DOI":"10.21608\/zumj.2020.31340.1864","volume":"0","author":"SM mohamed ehab, Mousa","year":"2020","unstructured":"mohamed ehab, Mousa SM Serum N-Acetyl-\u03b2-D-Glucosaminidase Level Assessment in Type 2 Diabetes Mellitus Patients with Ischemic Heart Disease. Zagazig Univ Med J. 2020;0(0):0\u20130. . https:\/\/doi.org\/10.21608\/zumj.2020.31340.1864.","journal-title":"Zagazig Univ Med J"},{"issue":"9","key":"5777_CR41","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1681\/ASN.2022010098","volume":"33","author":"C Liu","year":"2022","unstructured":"Liu C, Debnath N, Mosoyan G, Chauhan K, Vasquez-Rios G, Soudant C, Menez S, Parikh CR, Coca SG. Systematic Review and Meta-Analysis of Plasma and Urine Biomarkers for CKD Outcomes. J Am Soc Nephrol. 2022;33(9):1657\u201372. https:\/\/doi.org\/10.1681\/ASN.2022010098.","journal-title":"J Am Soc Nephrol"}],"container-title":["BMC Cardiovascular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12872-026-05777-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-026-05777-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-026-05777-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T22:04:23Z","timestamp":1781647463000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12872-026-05777-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,15]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5777"],"URL":"https:\/\/doi.org\/10.1186\/s12872-026-05777-x","relation":{},"ISSN":["1471-2261"],"issn-type":[{"value":"1471-2261","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,15]]},"assertion":[{"value":"10 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This research was conducted in accordance with the guidelines of the Declaration of Helsinki. The Ethical Committee of Mansoura University gave approval (Institutional Review Board [IRB] (code: MDP.24.05.153). All participants provided informed consent to participate in this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from participants for the publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"331"}}